Cell-free DNA methylomics identify tissue injury patterns in pediatric ARDS.

Summary

Plasma cfDNA methylation profiling can assign tissue-of-origin for injury in pediatric ARDS, enabling objective mapping of organ damage. This platform highlights actionable pathways to stratify patients and inform targeted therapies.

Key Findings

• Plasma cfDNA methylation signatures identify tissue injury patterns in children with severe lung injury/ARDS.
• This approach points to new therapeutic targets by revealing which tissues are affected.

Clinical Implications

cfDNA methylomics may guide risk stratification, monitoring of multi-organ involvement, and selection of targeted interventions in pediatric ARDS.

Limitations

• Sample size and validation cohorts are not specified in the abstract
• Clinical utility and impact on outcomes require prospective interventional validation

Future Directions

Validate cfDNA methylome tissue-injury panels in multi-center pediatric ARDS cohorts and integrate with clinical endpoints to guide trials.